China Resources Jiangzhong Pharmaceutical Co.,Ltd (SHA:600750)
China
· Delayed Price · Currency is CNY 25.67
+0.57 (2.27%)
Mar 10, 2026, 3:00 PM CST
SHA:600750 Revenue
China Resources Jiangzhong Pharmaceutical Co.,Ltd had revenue of 792.05M CNY in the quarter ending September 30, 2025, a decrease of -7.59%. This brings the company's revenue in the last twelve months to 4.24B, down -4.66% year-over-year. In the year 2024, China Resources Jiangzhong Pharmaceutical Co.,Ltd had annual revenue of 4.44B, down -2.59%.
Revenue (ttm)
4.24B
Revenue Growth
-4.66%
P/S Ratio
3.73
Revenue / Employee
1.01M
Employees
4,182
Market Cap
15.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.44B | -117.76M | -2.59% |
| Dec 31, 2023 | 4.55B | 668.03M | 17.19% |
| Dec 31, 2022 | 3.89B | 1.01B | 35.19% |
| Dec 31, 2021 | 2.87B | 432.52M | 17.72% |
| Dec 31, 2020 | 2.44B | -7.95M | -0.32% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Guangdong Zhongsheng Pharmaceutical | 2.45B |
| Shenzhen Hepalink Pharmaceutical Group | 5.38B |
| Hybio Pharmaceutical | 898.10M |
| Zhejiang Jiuzhou Pharmaceutical | 5.36B |
| Guobang Pharma | 5.94B |
| Shanghai Shyndec Pharmaceutical | 9.36B |